Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press14210.17650/1994-4098-2011-0-1-46-49MAMMOLOGY. TREATMENTМАММОЛОГИЯ. ЛЕЧЕНИЕCurrent feasibility of endocrine therapy for breast cancerСовременные возможности эндокринотерапии рака молочной железыVysotskayaI. V.ВысоцкаяИ. В.
Russian Federation
vysotskaya.irina@mail.ruI.M. Sechenov First Moscow State Medical University1-й МГМУ им. И.М. Сеченова250220111464925072014250720142011https://ojrs.abvpress.ru/ojrs/article/view/142

The paper considers the current feasibility of endocrine therapy for breast cancer (BC). It presents trials of the efficacy of fulvestrant in the treatment of patients with BC. Practically all clinical trials have demonstrated that the drug is well tolerated, without causing any significant systemic estrogen-like effects, as well as complications associated with the use of aromatase inhibitors.

Рассмотрены современные возможности эндокринотерапии рака молочной железы (РМЖ). Представлены исследования, посвященные изучению эффективности применения фулвестранта в лечении больных РМЖ. Практически во всех проведенных клинических исследованиях препарат продемонстрировал хорошую переносимость и отсутствие значимых системных эстрогеноподобных эффектов, а также осложнений, связанных с применением ингибиторов ароматазы.

breast cancerendocrine therapyfulvestrantрак молочной железыэндокринотерапияфулвестрант1. Parker M.G. Action of «pure» antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 1993;26:131–7.Parker M.G. Action of «pure» antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 1993;26:131–7.2. Dauvois S., White R., Parker M.G. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993;106(Pt 4):1377–88.Dauvois S., White R., Parker M.G. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993;106(Pt 4):1377–88.3. Bross P., Baird A., Chen G. et al. Fulvestrant in postmenopausal women with advanced breast cancer. Clin Cancer Res 2003;9:4309–17.Bross P., Baird A., Chen G. et al. Fulvestrant in postmenopausal women with advanced breast cancer. Clin Cancer Res 2003;9:4309–17.4. Shim W.S., Conaway M., Masamura S. et al. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 2000;141:396–405.Shim W.S., Conaway M., Masamura S. et al. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 2000;141:396–405.5. Chan C.M., Martin L.A., Johnston S.R. et al. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 2002;81:333–41.Chan C.M., Martin L.A., Johnston S.R. et al. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 2002;81:333–41.6. Martin L.-A., Farmer I., Johnston S.R.D. et al. Enhanced estrogen receptor (ER) a, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003;278:30458–68.Martin L.-A., Farmer I., Johnston S.R.D. et al. Enhanced estrogen receptor (ER) a, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003;278:30458–68.7. Jeng M.H., Shupnik M.A., Bender T.P. et al. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 1998;139(10):4164–74.Jeng M.H., Shupnik M.A., Bender T.P. et al. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 1998;139(10):4164–74.8. Howell A. Fulvestrant ('Faslodex'): current and future role in breast cancer management. Crit Reviews Oncol/Hematol 2006;57:265–73.Howell A. Fulvestrant ('Faslodex'): current and future role in breast cancer management. Crit Reviews Oncol/Hematol 2006;57:265–73.9. Steger G., Bartsch R., Wenzel C. et al. Fulvestrant (Faslodex®) in metastatic breast cancer. Breast Cancer Res Treat 2003;82 (Suppl 1):104; abstr 437.Steger G., Bartsch R., Wenzel C. et al. Fulvestrant (Faslodex®) in metastatic breast cancer. Breast Cancer Res Treat 2003;82 (Suppl 1):104; abstr 437.10. Howell A., Robertson J.F., Quaresma Albano J. et al. Fulvestrant, formerly ICI 182 780, is as effective as Anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396–403.Howell A., Robertson J.F., Quaresma Albano J. et al. Fulvestrant, formerly ICI 182 780, is as effective as Anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396–403.11. Ingle J.N., Rowland K.M., Suman V.J. et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group. Breast Cancer Res Treat 2004;88 (Suppl 1):38; abstr 409.Ingle J.N., Rowland K.M., Suman V.J. et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group. Breast Cancer Res Treat 2004;88 (Suppl 1):38; abstr 409.12. Perey L., Paridaens R., Nole F. et al. Fulvestrant (FaslodexTM) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and aromatase inhibitors: update of a phase II SAKK trial. Breast Cancer Res Treat 2004;88(Suppl 1):6048.Perey L., Paridaens R., Nole F. et al. Fulvestrant (FaslodexTM) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and aromatase inhibitors: update of a phase II SAKK trial. Breast Cancer Res Treat 2004;88(Suppl 1):6048.13. Howell A., Robertson J.F., Abram P. et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22:1605–13.Howell A., Robertson J.F., Abram P. et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22:1605–13.14. Robertson J.F., Nicholson R.I., Bundred N.J. et al. Comparison of the short-term biological effects of 7alpha-9-(4,4,5,5,5- pentafluoropentylsulfinyl)-nonyl.estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001;61:6739–46.Robertson J.F., Nicholson R.I., Bundred N.J. et al. Comparison of the short-term biological effects of 7alpha-9-(4,4,5,5,5- pentafluoropentylsulfinyl)-nonyl.estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001;61:6739–46.15. Osborne C.K., Pippen J., Jones S.E. et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386–95.Osborne C.K., Pippen J., Jones S.E. et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386–95.16. Bauerschlag D.O., Schem C., Jonat W. et al.; University of Schleswig–Holstein, Kiel, Germany. Clinical experience using fulvestrant in hormone responsive metastatic breast cancer. ASCO 2006; abstr 10749.Bauerschlag D.O., Schem C., Jonat W. et al.; University of Schleswig–Holstein, Kiel, Germany. Clinical experience using fulvestrant in hormone responsive metastatic breast cancer. ASCO 2006; abstr 10749.17. Petruzelka L., Zimovjanova M., Konopasek B. et al. Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy — updated results from an expanded access programme. Ann Oncol 2004;15(Suppl 3):136.Petruzelka L., Zimovjanova M., Konopasek B. et al. Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy — updated results from an expanded access programme. Ann Oncol 2004;15(Suppl 3):136.18. Robertson J.F.R., Semiglazov V., Gee J.M., Armstrong J. Effects of fulvestrant in premenopausal women with oestrogen receptor-positive primary breast cancer. Eur J Cancer Suppl 2004;2:73; abstr 59.Robertson J.F.R., Semiglazov V., Gee J.M., Armstrong J. Effects of fulvestrant in premenopausal women with oestrogen receptor-positive primary breast cancer. Eur J Cancer Suppl 2004;2:73; abstr 59.19. Piccart-Gebhart M.J., Loi S.M. Fulvestrant — ready to start its journey in the breast cancer adjuvant endocrine world. Eur J Cancer 2005;41:341–3.Piccart-Gebhart M.J., Loi S.M. Fulvestrant — ready to start its journey in the breast cancer adjuvant endocrine world. Eur J Cancer 2005;41:341–3.20. Osborne C.K., Coronado-Heinsohn E.B., Hilsenbeck S.G. et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995;87:746–50.Osborne C.K., Coronado-Heinsohn E.B., Hilsenbeck S.G. et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995;87:746–50.21. Robertson J.F., Howell A., Gorbunova V.A. et al. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast Cancer Res Treat 2005;92(2):169–74.Robertson J.F., Howell A., Gorbunova V.A. et al. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast Cancer Res Treat 2005;92(2):169–74.22. Robertson J.F., Osborne C.K., Howell A. et al. Fulvestrant versus anastrozole forRobertson J.F., Osborne C.K., Howell A. et al. Fulvestrant versus anastrozole forthe treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98(2):229–38.23. Agraval A., Hannon R.A., Cheung K.L. et al. Bone turnover markers in postmenopausal breast cancer patients treated with fulvestrant. ASCO 2006; abstr 680.Agraval A., Hannon R.A., Cheung K.L. et al. Bone turnover markers in postmenopausal breast cancer patients treated with fulvestrant. ASCO 2006; abstr 680.24. Steger G., Bartsch R., Wenzel C. et al. Fulvestrant (FUL) and goserelin (GOS) in premenopausal women with advanced, hormone-sensitive breast cancer: A pilot study. J Clin Oncol 2005;23:55; abstr 708.Steger G., Bartsch R., Wenzel C. et al. Fulvestrant (FUL) and goserelin (GOS) in premenopausal women with advanced, hormone-sensitive breast cancer: A pilot study. J Clin Oncol 2005;23:55; abstr 708.25. Piccart-Gebhart M.J., Loi S.M. Fulvestrant — ready to start its journey in the breast cancer adjuvant endocrine world. Eur J Cancer 2005;41:341–3.Piccart-Gebhart M.J., Loi S.M. Fulvestrant — ready to start its journey in the breast cancer adjuvant endocrine world. Eur J Cancer 2005;41:341–3.26. Buzdar A.U. Fulvestrant — a novel estrogen receptor antagonist for the treatment of advanced breast cancer. World J Surg Oncol 2008;1(6):128.Buzdar A.U. Fulvestrant — a novel estrogen receptor antagonist for the treatment of advanced breast cancer. World J Surg Oncol 2008;1(6):128.